BOSTON--The genomic tumult within tumor cells has provided scientists at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard with clues to an entirely new class of genes that may serve as an Achilles' ...
Aug 15, 2012
0
0
Since anti-cancer drugs are carried to tumors by the bloodstream, abnormal blood vessel development can hamper delivery. In a paper published Aug. 14 in Cancer Cell, researchers at Sanford-Burnham Medical Research Institute ...
Aug 13, 2012
0
0
Patients in early clinical trials of new-style targeted cancer therapies appear to have a much lower risk of the most serious side-effects than with traditional chemotherapy, according to a new analysis.
Aug 7, 2012
0
0
Researchers have created the first mouse model demonstrating the role of a cancer promoting gene, Astrocyte elevated gene-1 (AEG-1), in hepatocellular carcinoma, or liver cancer. The mouse model represents a critical step ...
Jul 6, 2012
0
0
German pharmaceuticals maker Merck KGaA said Thursday that phase III clinical trials of its gastric cancer drug Erbitux had shown no benefits for patients.
Jul 5, 2012
0
0
A study conducted at Boston University School of Medicine (BUSM) demonstrates an effective combination therapy for breast cancer cells in vitro. The findings, published in the July 2012 issue of Anticancer Research, raise ...
Jul 2, 2012
0
0
(Medical Xpress) -- The discovery of a new drug for liver cancer by researchers of The Hong Kong Polytechnic University (PolyU) and local medical practitioner has born fruit. After completing clinical trials locally, the ...
Jun 29, 2012
0
0
Cancer drug development is known to be too slow, costly and fraught with failure. Now the U.S. Food and Drug Administration is issuing recommendations for breast cancer trials that would substantially accelerate patient access ...
Jun 4, 2012
0
0
Research led by St. Jude Children's Research Hospital investigators suggests that safeguarding cell survival and maintaining a balanced immune system is just the start of the myeloid cell leukemia sequence 1 (MCL1) protein's ...
Apr 30, 2012
0
0
BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted therapeutics called AccurinsTM, announced today the presentation of late-breaker clinical data for BIND-014, ...
Apr 4, 2012
0
0
